Form 4: Insulet Executive Sells Shares Under 10b5-1 Plan

Insulet's EVP, CPXO, Eric Benjamin, sold 4,263 shares of common stock for $332.23 per share on August 21, 2025, as part of a pre-arranged trading plan.

Summary

• Eric Benjamin, EVP, CPXO of Insulet Corporation (PODD), reported a transaction involving company common stock.
• On August 21, 2025, Mr. Benjamin disposed of 4,263 shares of common stock.
• The shares were sold at a price of $332.23 per share.
• This transaction was executed pursuant to an existing Rule 10b5-1 trading plan.
• Following this transaction, Mr. Benjamin beneficially owns 16,736 shares of Insulet common stock.
• The reported beneficial ownership includes 93 shares acquired under the Insulet Corporation Employee Stock Purchase Plan since the last Form 4 filing.

Sentiment

Score: 4

Explanation: The sale of shares by an executive, even under a 10b5-1 plan, can be perceived as a slight negative. However, the pre-planned nature mitigates the impact, and the acquisition of shares via ESPP offers a minor positive counterpoint.

Positives

• The transaction was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled sale not based on immediate insider information.
• The reporting person acquired 93 shares through the Employee Stock Purchase Plan, demonstrating continued employee investment in the company.

Negatives

• An executive selling a significant number of shares (4,263) could be perceived as a negative signal by some investors, even if pre-planned.

Future Outlook

Not applicable; this Form 4 filing reports a past insider transaction and does not provide forward-looking statements or guidance.

Industry Context

This filing reports a routine insider transaction for Insulet Corporation, a medical device company specializing in insulin management. Such transactions are common across all industries for executives managing personal portfolios, especially when executed under Rule 10b5-1 plans, which are designed to prevent insider trading allegations.

Corporate Governance

Stakeholder Impact

• Shareholders: May interpret the executive's sale as a neutral to slightly negative signal, though the 10b5-1 plan provides context that it's not based on new, adverse information.

Key Dates

Recommendation

While an executive sale of shares can sometimes be a negative signal, this transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests the sale is for personal financial planning rather than a reaction to new, adverse company information. The filing itself does not provide enough fundamental information to warrant a change in investment recommendation, thus a 'hold' stance is appropriate based solely on this Form 4.

Keywords

Insulet Corporation, PODD, Insider Trading, Form 4, Executive Stock Sale, Rule 10b5-1, Employee Stock Purchase Plan, Eric Benjamin, Common Stock